Status:
COMPLETED
Activity of Essential Fatty Acid Elongation/Desaturation Pathway During Early Life in Human Infants, In Vivo
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Fatty Acid Metabolism
Eligibility:
All Genders
Brief Summary
We will test the following hypotheses: 1. The activity of the desaturating/elongating enzymes assessed by the in vivo conversion of deuterated a-linolenic and linoleic acids to DHA and AA, respective...
Detailed Description
We will test the following hypotheses: 1. The activity of the desaturating/elongating enzymes assessed by the in vivo conversion of deuterated a-linolenic and linoleic acids to DHA and AA, respective...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Newborns with birth weights appropriate for their gestational age born at 28, 32, 36 and 40 weeks gestation that are recovering from common neonatal morbidity will be recruited to enter the study before 5 days of age. This disease condition will not be life threatening at the time of study.
- The typical disease conditions expected based on the pilot phase of study are infants recovering from asphyxia, infants recovering from transient tachypnea, infants recovering from suspect pneumonia, infants recovering from hyaline membrane disease.
- Hyperbilirubinemia in conjunction with disease condition will not be a reason for exclusion.
- Newborns with birth weights below the tenth percentile of the weight distribution for a given gestational age born at 30-34 and 36-38 weeks gestation.
- Will include infants born at 28 to 40 weeks who are free of major neonatal morbidity and will be recruited to enter the study at 10 days of age.
- EXCLUSION CRITERIA:
- Maternal factors which may affect their fatty acid metabolism of the neonate.
- Vegetarian or vegan diet during pregnancy
- Metabolic disease which may affect essential fatty acid status of the fetus (hyperlipidemia, diabetes)
- Postnatal factors:
- Birth weight inadequate for gestational age (birth weight below the 10th percentile or above the 90th percentile for gestational age)
- Significant acute neonatal morbidity which interferes with normal lipid metabolism during the study period. Infants who are recovering from common neonatal morbidities that do not have obvious effects on elongase/desaturase activity will not be excluded.
- Feeding other than prescribed for the study.
Exclusion
Key Trial Info
Start Date :
June 8 1993
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 13 2010
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00342303
Start Date
June 8 1993
End Date
July 13 2010
Last Update
July 2 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica Presbiteriana Madre Hijo
Santiago, Chile
2
Hospital Luis Tisne
Santiago, Chile